Pancreatic portal hypertension is a distinct type of portal hypertension caused by various pancreatic diseases or by pancreatic surgery. Unlike the far more common portal hypertension driven by cirrhosis of the liver, this variant arises when inflammation, cysts, tumors, or scarring in the pancreas compress or obstruct the splenic vein and neighboring splanchnic vessels. Blood that cannot drain through its usual route finds alternative channels, engorging vessels around the stomach and esophagus and enlarging the spleen. The result is a condition that mimics liver disease on the surface but has an entirely different anatomy and, crucially, a different treatment logic.

The clinical significance of the new consensus lies partly in a quiet epidemiological shift. According to the guideline authors, the detection rate of pancreatic portal hypertension has steadily increased in recent years with the widespread application of advanced imaging techniques and endoscopy. Computed tomography and magnetic resonance imaging now routinely capture the pancreatic region in exquisite detail, while endoscopic ultrasound allows physicians to peer directly at the vessels surrounding the pancreas. Diseases that once went unrecognized are now being identified with growing frequency, making a standardized management framework increasingly urgent.

Yet the condition remains notoriously difficult to catch early. The consensus panel notes that the clinical manifestations of pancreatic portal hypertension are often insidious, compromising early identification. Patients may carry the vascular changes for years without symptoms, and the first warning signs frequently emerge only at an advanced stage. By that point, some complications, such as splenomegaly and upper gastrointestinal bleeding, have already taken hold. Bleeding from engorged gastric varices can be dramatic and life threatening, while an enlarged spleen can trap platelets and complicate the broader management of the underlying pancreatic disease.

To build the guideline, the Chinese Society of Gastroenterology of the Chinese Medical Association invited a panel of skilled experts to participate in a Delphi consensus process, systematically reviewing and discussing the available evidence on the causes, risk factors, clinical manifestations, diagnosis, therapy, and prognostic assessment of pancreatic portal hypertension. The Delphi method is a structured technique for extracting reliable group judgment from a large panel: experts answer questionnaires independently, the results are aggregated and fed back, and the process repeats until statements stabilize. After three rounds of questionnaire surveys and votes, the panel formulated 19 consensus statements to provide clinical guidance on the diagnosis and management of the condition.

The scope of the consensus is deliberately broad. By covering etiology, risk factors, clinical presentation, diagnostic strategy, therapeutic options, and prognostic assessment in a single document, the guideline fills a gap that existing publications on pancreatic diseases or portal hypertension had left open. Although the concept of pancreatic portal hypertension has been recognized in existing guidelines and consensus documents on the management of pancreatic diseases or portal hypertension, its management strategy had never been comprehensively summarized. Clinicians confronting a patient with pancreatic disease and unexplained gastric varices or splenic enlargement have had to piece together guidance from scattered sources, and the new consensus aims to end that improvisation.

Technically, the diagnostic challenge centers on distinguishing pancreatic portal hypertension from cirrhotic portal hypertension and from other causes of splanchnic vein thrombosis. Cross-sectional imaging plays the decisive role: contrast-enhanced computed tomography and magnetic resonance imaging can reveal the obstructing pancreatic lesion, the occluded or compressed splenic vein, and the collateral vessels that betray the redirected blood flow. Endoscopic evaluation identifies the varices that carry bleeding risk, while laboratory findings such as thrombocytopenia from hypersplenism can provide supporting clues. The consensus framework gives clinicians a structured pathway for assembling these pieces into a confident diagnosis, even when the liver itself is entirely healthy.

On the therapeutic side, the management logic differs fundamentally from that of cirrhotic portal disease. Because the obstruction is often localized to the splenic vein, treating the underlying pancreatic lesion can sometimes restore normal venous drainage, and interventions aimed at the vascular obstruction itself, including endovascular approaches, have been explored in the literature. The consensus statements address how to weigh bleeding risk against the risks of intervention, how to manage acute upper gastrointestinal bleeding when it occurs, and how to coordinate vascular care with the treatment of the primary pancreatic condition, whether that is acute pancreatitis, chronic pancreatitis, autoimmune pancreatitis, or a pancreatic tumor.

The panel was large and geographically diverse, drawing gastroenterologists, endoscopists, interventional radiologists, hepatobiliary surgeons, and intensive care specialists from major hospitals across China, from Shenyang in the northeast to Chengdu, Shanghai, Guangzhou, and Xi’an. Corresponding authors include Xingshun Qi of the General Hospital of Northern Theater Command, Hao Wu and Chengwei Tang of West China Hospital, Sichuan University, and Xiaozhong Guo of the General Hospital of Northern Theater Command. Four junior researchers, Xingshun Qi, Yuhang Yin, Zhiyin Huang, and Yuzheng Zhuge, contributed equally to the work, which was partially supported by the National Key R&D Program of China.

The methodological rigor of the consensus reflects modern guideline standards. The panel employed structured evidence frameworks, including PICO and PECO question formats for framing clinical questions, and used the GRADE system for grading the quality of evidence behind each recommendation. Reporting followed the RIGHT checklist for practice guidelines, and the document was appraised with the AGREE II instrument. Literature searches spanned Chinese databases such as CNKI and VIP alongside international sources, ensuring that both Chinese clinical experience and global evidence informed the final statements. The authors declare no competing interests, and the guideline is published under a Creative Commons license allowing free access for clinicians worldwide.

For the international medical community, the significance of the consensus extends beyond China’s borders. Pancreatic portal hypertension is a global condition, arising wherever pancreatitis, pseudocysts, tumors, or pancreatic surgery compromise the splenic vein, and clinicians on every continent face the same diagnostic and therapeutic dilemmas. A comprehensive, openly available framework for the causes, risk factors, clinical manifestations, diagnosis, therapy, and prognostic assessment of the disease gives physicians everywhere a reference point for building their own local protocols. As advanced imaging continues to reveal more cases that once went undetected, the demand for such standardized guidance will only grow, and the 19 statements now offer a foundation that future international guidelines can refine and extend.

Subject of Research: Medicine

Article Title: Chinese consensus on the management of pancreatic portal hypertension

Article References: Qi, X., Yin, Y., Huang, Z., Zhuge, Y., Cai, S., Chen, M., Chen, P., Chen, S., Chen, W., Ding, Z., Du, Y., Guo, G., Guo, W., He, F., He, W., Hu, S., Huang, L., Ke, L., Kong, D., … Tang, C. (2026). Chinese consensus on the management of pancreatic portal hypertension. BMC Medicine. https://doi.org/10.1186/s12916-026-05289-7

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05289-7

Keywords: pancreatic portal hypertension, portal hypertension, consensus, gastrointestinal bleeding, splenomegaly, BMC Medicine, Delphi, pancreatic disease, Chinese, management, pancreatic, portal

In classical medicine, ileus referred to a violent, often fatal condition of the abdomen in which the intestines were believed to be gripped by pain and dysfunction. Ancient and early modern physicians used the term for what they described as intestinal colic or a twisting suffering of the gut, a syndrome recognized by severe abdominal distension, vomiting, and collapse. The word carried an aura of dread. For centuries, ileus was less an anatomical diagnosis than a description of a catastrophic clinical picture, one that physicians could observe but rarely explain and almost never treat.

As Ballantyne documented in a 1984 review of the term’s changing definition over three millennia, the modern era brought a decisive shift. By the nineteenth and early twentieth centuries, surgeons increasingly distinguished between mechanical obstruction of the bowel, in which a physical blockage halts the passage of intestinal contents, and paralytic or adynamic ileus, in which the bowel wall simply stops moving. This distinction mattered enormously for practice. A mechanical obstruction demanded surgical relief, while a paralyzed bowel called for decompression, supportive care, and patience. The word ileus, once a single ominous label, had split into two conceptually different diseases, and the tension between those meanings would soon shape how one of pediatrics’ signature conditions was first recognized.

It was against this backdrop that the earliest reports of meconium ileus appeared. In 1905, Karl Landsteiner, the Viennese pathologist better known for his discovery of the ABO blood groups, published a description of intestinal obstruction caused by inspissated, or thickened and dried, meconium, which he linked to pancreatic disease. Writing in German, Landsteiner described a bowel blocked not by a band, a volvulus, or an atresia, but by abnormally dense fetal intestinal contents. His observation connected two organ systems, gut and pancreas, in a way that would prove prophetic, though the full significance of that connection took decades to appreciate.

The term meconium ileus itself emerged in the clinical literature shortly afterward. In 1919, Bullowa and Brennan reported a case of intrauterine intestinal obstruction from inspissated and impacted meconium in the Journal of the American Medical Association, framing the problem as a mechanical obstruction present before birth. Here the older, mechanical sense of ileus was doing quiet work: the authors were not describing a paralyzed bowel but a bowel physically plugged by tenacious meconium. The phrase captured a paradox that would puzzle clinicians for years, namely that a newborn could be born already obstructed by a substance that should have passed harmlessly in the first days of life.

Through the 1920s and 1930s, case reports accumulated. In 1936, Dodd published a case report in the Journal of Pediatrics of intestinal obstruction due to meconium ileus in a newborn infant, and the same year Eliason and Johnson addressed the diagnostic features of ileus in the journal Radiology, reflecting the growing role of abdominal radiography in distinguishing patterns of bowel obstruction. Radiographs allowed clinicians to see dilated loops of bowel and, in some cases, a characteristic granular or ground-glass appearance where thick meconium mixed with air. Imaging gave the condition a visible signature and helped separate it from other causes of neonatal obstruction such as atresia, stenosis, and volvulus.

The decisive conceptual breakthrough came in 1936 and 1938. In 1936, Fanconi, Uehlinger, and Knauer published their description of the celiac syndrome associated with congenital cystic fibromatosis of the pancreas and bronchiectasis, drawing together the intestinal, pancreatic, and pulmonary features that had previously been reported in isolation. Two years later, Dorothy Andersen, in a landmark clinical and pathological study in the American Journal of Diseases of Children, defined cystic fibrosis of the pancreas as a distinct disease and established its relationship to the celiac-like syndrome of infants. Within this new framework, meconium ileus found its place: it was not a random mechanical accident of fetal life but the earliest clinical manifestation of a hereditary disorder that thickened secretions throughout the body.

Once cystic fibrosis was defined, the meaning of meconium ileus settled into its modern form. The condition is now understood as neonatal intestinal obstruction caused by abnormally viscous meconium, the product of deficient pancreatic enzyme secretion and altered mucus, which accumulates in the terminal ileum and cecum and produces a mechanical blockage. In the vocabulary of the early twentieth century, that made meconium ileus a true mechanical ileus, in the tradition of Steele’s 1901 discussion of ileus due to mechanical obstruction to the fecal current, rather than a paralytic ileus of the kind Wathen described in his 1909 JAMA paper on postoperative ileus. The newborn bowel in meconium ileus is not lazy; it is blocked, and it strains against a plug of material too thick to pass.

Zarka’s commentary highlights how this history illustrates a broader point about medical language. The word ileus arrived in the meconium literature carrying its ancient sense of severe intestinal suffering, was refined by surgeons into a distinction between mechanical and adynamic obstruction, and then, in the phrase meconium ileus, preserved a specific mechanical meaning that clinical experience gradually clarified. What began as a descriptive label for a mysterious neonatal catastrophe became, through the accumulation of cases, the application of new imaging techniques, and the recognition of cystic fibrosis, a precise diagnostic entity with a defined pathophysiology. The forgotten layers of the term’s meaning were not lost so much as overwritten, and revisiting them reveals how much of modern terminology encodes older debates.

The story also underscores the value of clinical observation in advance of molecular understanding. Landsteiner linked inspissated meconium to pancreatic disease decades before the genetic basis of cystic fibrosis was known. Bullowa and Brennan recognized intrauterine obstruction before any treatment was possible. Andersen’s synthesis transformed scattered reports into a coherent disease concept. Each step depended on clinicians taking seriously what they saw at the bedside and in the pathology laboratory, and on a vocabulary flexible enough, despite its tangled history, to carry those observations forward. In the case of meconium ileus, the curious history of a single word helped keep a forgotten meaning alive long enough for medicine to give it a name, a mechanism, and eventually a place within one of the most common hereditary diseases of childhood.

Subject of Research: The historical evolution of the term ileus and its role in the recognition of meconium ileus as an early manifestation of cystic fibrosis

Article Title: The curious history of meconium ileus: how clinical experience revived a forgotten meaning

Article References: Zarka, A. (2026). The curious history of meconium ileus: how clinical experience revived a forgotten meaning. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06777-x

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06777-x

Keywords: meconium ileus, ileus, cystic fibrosis, history of medicine, Karl Landsteiner, Dorothy Andersen, pediatric radiology, intestinal obstruction, neonatology, medical terminology, pancreatic disease, clinical history